ArticleEndocrinology, diabetes & metabolism case reports2025
Severe hypertriglyceridaemia with length-related small fibre sensory neuropathy as a complication of previous gestational diabetes mellitus.
Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Women with a history of gestational diabetes mellitus have preserved sensory nerve-mediated dilatation in the cutaneous microvasculature.Experimental physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: Gestational diabetes mellitus (GDM) is a known risk factor for dyslipidaemias. Insulin resistance and the associated dyslipidaemia, particularly hypertriglyceridaemia, have been less frequently linked to peripheral nerve dysfunction, including small fibre sensory neuropathy. The relationship between metabolic disturbances, such as hypertriglyceridaemia, and neuropathy warrants further exploration and has gained increasing recognition in recent studies. This case highlights the potential neurological consequences of lipid abnormalities in women with a history of GDM. A 38-year-old woman presented to an endocrinologist with a 4-week history of paraesthesias and incidental findings of significantly elevated triglycerides (78.4 mmol/L) and total cholesterol (14.7 mmol/L). Initially, numbness began in her left first toe, spreading to other toes on the left foot, and then to the right foot, accompanied by hyperalgesia in fifth fingers bilaterally. She had no history of trauma or back injuries. Her medical history included insulin-dependent GDM and HELLP syndrome 4 years prior, endometriosis, and adenomyosis. With persistently high lipid levels (cholesterol: 12.1 mmol/L; triglycerides: 18.5 mmol/L), she was admitted to ICU for urgent lipid-lowering treatment but experienced hypoglycaemia on an insulin-dextrose infusion. Repeat triglycerides the next day were 13.1 mmol/L. A neurologist diagnosed her with small fibre sensory neuropathy secondary to hypertriglyceridaemia. Treatment with fenofibrate, high-dose fish oil, and a low-fat, low-carbohydrate diet was initiated with outpatient endocrinologist follow-up. Hypertriglyceridaemia is a significant health concern, potentially leading to severe complications such as peripheral neuropathy. Early intervention to optimise lipid levels is essential to prevent adverse outcomes. Learning points: GDM is known to be a risk factor for dyslipidaemias. Hypertriglyceridaemia can contribute to small fibre sensory neuropathy via mechanisms including microvascular ischaemia, oxidative stress, and inflammation affecting peripheral nerves. Diagnosis requires clinical correlation with lipid profiles and neurological findings, and exclusion of other causes through targeted investigations such as nerve conduction studies and autoimmune screening. Early recognition of hypertriglyceridaemia is essential to prevent complications such as neuropathy. Acute management may involve insulin-dextrose infusion in cases of severe elevation, while long-term treatment includes fibrates, omega-3 fatty acids, and dietary modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.